Erythromycin use prior to endoscopy improves gastric mucosa visualisation

In a new study by Diego Adao and team it was found that when erythromycin  used prior to endoscopy may enhance the ability to see the gastrointestinal mucosa and reduce the need for blood transfusions slightly. The findings were published in Cochrane Database of Systematic Reviews.

The only effective treatment for upper gastrointestinal hemorrhage is an upper GI endoscopy (UGIH). Nonetheless, the gastric mucosa may only be partially visible at presentation in up to 13% of patients who have an upper endoscopy. Erythromycin accelerates stomach emptying by acting as a motilin receptor agonist in the upper GI tract, which may result in higher visual clarity and more therapeutic efficacy. The benefits and risks of erythromycin in UGIH are not clear, nevertheless. In order to assess the advantages and disadvantages of erythromycin before endoscopy in people with acute upper gastrointestinal haemorrhage to any other medication, no treatment, or a placebo, this study was carried out.

For this investigation, traditional, thorough Cochrane search techniques were employed. The most recent search was done on October 15, 2021. Erythromycin before endoscopy was compared to any other medication, no treatment, or a placebo before endoscopy in adults with acute UGIH in the included randomised controlled trials (RCTs). The UGIH-related mortality and serious adverse events were the major outcomes, were all-cause mortality, stomach mucosa visualisation, rebleeding, non-serious adverse events, blood transfusion, and rescue invasive intervention were the secondary endpoints. To rate the degree of certainty in the evidence supporting each conclusion, GRADE criteria were utilised.